COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB AMONG PRETERM INFANTS COVERED BY MEDICAID IN THE UNITED STATES

被引：1
|
作者：
Weiner, L. B. [1 ]
Polak, M. J. [2 ]
Masaquel, A. [3 ]
Mahadevia, P. J. [3 ]
机构：
[1] Upstate Med Univ, Syracuse, NY USA
[2] W Virginia Univ, Sch Med, Morgantown, WV 26506 USA
[3] MedImmune, Gaithersburg, MD USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.655
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A118 / A118
页数：1
相关论文
共 50 条
  • [31] Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation
    Yeo, Kee Thai
    Yung, Chee Fu
    Khoo, Poh Choo
    Saffari, Seyed Ehsan
    Sng, Jane Swee Peng
    How, Mee See
    Quek, Bin Huey
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (02): : 279 - 287
  • [32] Effectiveness of Palivizumab in Respiratory Syncytial Virus Prophylaxis in Children with Cystic Fibrosis
    Winterstein, Almut G.
    Eworuke, Efe
    Xu, Dandan
    Schuler, Pamela
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 148 - 148
  • [33] Healthcare Utilization Among Infants Covered by Medicaid and Newly Diagnosed With Respiratory Syncytial Virus
    Suh, Mina
    Movva, Naimisha
    Jiang, Xiaohui
    Reichert, Heidi
    Pastula, Susan T.
    Sacks, Naomi C.
    Frankenfeld, Cara
    Fryzek, Jon P.
    Simoes, Eric A. F.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (04):
  • [34] The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Lanctot, Krista L.
    Masoud, Shababa T.
    Paes, Bosco A.
    Tarride, Jean-Eric
    Chiu, Aaron
    Hui, Charles
    Francis, Philip L.
    Oh, Paul I.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3223 - 3237
  • [35] Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid's high-risk, children
    Shireman, TI
    Braman, KS
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2002, 156 (12): : 1251 - 1255
  • [36] Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
    Rohan C. Parikh
    Kimmie K. McLaurin
    Andrea V. Margulis
    Josephine Mauskopf
    Christopher S. Ambrose
    Melissa Pavilack
    Sean D. Candrilli
    Infectious Diseases and Therapy, 2017, 6 : 477 - 486
  • [37] Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
    Parikh, Rohan C.
    McLaurin, Kimmie K.
    Margulis, Andrea V.
    Mauskopf, Josephine
    Ambrose, Christopher S.
    Pavilack, Melissa
    Candrilli, Sean D.
    INFECTIOUS DISEASES AND THERAPY, 2017, 6 (04) : 477 - 486
  • [38] BURDEN OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND POTENTIAL IMPACT OF PROPHYLAXIS IN INFANTS IN SWEDEN: A COST-EFFECTIVENESS ANALYSIS
    Neovius, K.
    Buesch, K.
    Neovius, M.
    ACTA PAEDIATRICA, 2010, 99 : 96 - 97
  • [39] Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
    Blanken, Maarten O.
    Frederix, Geert W.
    Nibbelke, Elisabeth E.
    Koffijberg, Hendrik
    Sanders, Elisabeth A. M.
    Rovers, Maroeska M.
    Bont, Louis
    EUROPEAN JOURNAL OF PEDIATRICS, 2018, 177 (01) : 133 - 144
  • [40] Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
    Maarten O. Blanken
    Geert W. Frederix
    Elisabeth E. Nibbelke
    Hendrik Koffijberg
    Elisabeth A. M. Sanders
    Maroeska M. Rovers
    Louis Bont
    European Journal of Pediatrics, 2018, 177 : 133 - 144
12345